



HAL
open science

Mineralocorticoid receptor knockout in Schwann cells alters myelin sheath thickness

Alberto González-Mayoral, Axel Eid, Razmig Derounian, Virginia Sofia Campanella, Andreia da Silva Ramos, Romy El Khoury, Charbel Massaad,
Damien Le Menuet

► **To cite this version:**

Alberto González-Mayoral, Axel Eid, Razmig Derounian, Virginia Sofia Campanella, Andreia da Silva Ramos, et al.. Mineralocorticoid receptor knockout in Schwann cells alters myelin sheath thickness. *Journal of Endocrinology*, 2023, 258 (2), pp.e220334. 10.1530/JOE-22-0334 . inserm-04163081

HAL Id: inserm-04163081

<https://inserm.hal.science/inserm-04163081v1>

Submitted on 17 Jul 2023

HAL is a multi-disciplinary open access archive for the deposit and dissemination of scientific research documents, whether they are published or not. The documents may come from teaching and research institutions in France or abroad, or from public or private research centers.

L'archive ouverte pluridisciplinaire **HAL**, est destinée au dépôt et à la diffusion de documents scientifiques de niveau recherche, publiés ou non, émanant des établissements d'enseignement et de recherche français ou étrangers, des laboratoires publics ou privés.

1 **Mineralocorticoid Receptor knockout in Schwann cells alters myelin**
2 **sheath thickness**

3 Alberto González-Mayoral^{1,2}, Axel Eid^{1,3}, Razmig Derounian¹, Virginia Sofia Campanella¹,
4 Andreia da Silva Ramos¹, Romy El Khoury¹, Charbel Massaad¹, Damien Le Menuet^{1*}

5 1.INSERM UMRS 1124 (T3S), Faculty of Basic and Biomedical Sciences, *Université Paris*
6 *Cité*, Paris, France.

7 2. Current address: Paris Brain Institute-*Institut du Cerveau*, CNRS UMR7225, INSERM
8 U1127, *Hôpital de la Pitié Salpêtrière*, Paris, France

9 3. Current address: INSERM UMR 1195 (DHNS), Faculty of Medicine, *Université Paris-*
10 *Saclay*, Le Kremlin-Bicêtre, France.

11

12 * Corresponding author:

13 Damien Le Menuet, PhD

14 INSERM T3S (UMRS_1124)

15 Myelination and Nervous System Pathologies

16 45 rue des Saints Pères

17 75006 Paris

18 France

19 Tel +33 1 76 53 43 82

20 Email: damien.le-menuet@inserm.fr

21 <https://orcid.org/0000-0002-0802-7190>

22

23

24 **Short title:** MR, a new player in Schwann Cells

25

26

27 **Keywords:** Peripheral Nervous System, Schwann Cells, Glucocorticoids, Mineralocorticoid
28 Receptor

29

30

31 **Abstract**

32 Myelination allows fast and synchronized nerve influxes and is provided by Schwann cells in
33 the peripheral nervous system. Glucocorticoid hormones are major regulators of stress,
34 metabolism and immunity affecting all tissues. They act by binding to two receptors, the low
35 affinity glucocorticoid receptor (GR) and the high affinity mineralocorticoid receptor (MR). Little
36 is known on the effect of glucocorticoid hormones on the PNS and this study focuses on
37 deciphering the role of MR in peripheral myelination. In this work, the presence of a functional
38 MR in Schwann cells is demonstrated and the expression of MR protein in mouse sciatic nerve
39 SC is evidenced. Besides, knockout of MR in SC (SCMRKO using Cre-lox system with
40 *DesertHedgeHog* (Dhh) Cre promoter) was undertaken in mice. SCMRKO was not associated
41 with alterations of performance in motor behavioral tests on 2- to 6-month old male mice
42 compared to their controls. No obvious modifications of myelin gene expression or MR
43 signaling gene expression were observed in the SCMRKO sciatic nerves. Nevertheless, *Gr*
44 transcript and GR protein amounts were significantly increased in SCMRKO nerves compared
45 to controls, suggesting a possible compensatory effect. Besides, an increase in myelin sheath
46 thickness was noted for axons with perimeters larger than 15 μm in SCMRKO illustrated by a
47 significant 4.5 % reduction in g-ratio (axon perimeter/myelin sheath perimeter). Thus, we
48 defined MR as a new player in peripheral system myelination and in SC homeostasis.

49

50

51 **Introduction**

52 Myelin sheaths allow rapid and coordinated nerve influx in vertebrates. In the peripheral
53 nervous system (PNS), myelination is insured by Schwann cells (SC) (Boullerne 2016), each
54 SC myelinating a unique axon. Alternatively, small caliber axons of less than 1 μm in diameter
55 and with low conduction velocities are grouped together by non-myelinating SC (Salzer 2012).
56 Myelin lesions occur in several pathologies including auto-immune diseases such as Guillain–
57 Barré syndrome (Shahrizaila *et al.* 2021), genetic diseases such as Charcot-Marie-Tooth often
58 caused by mutations in myelin-associated genes (Higuchi & Takashima 2022), and diabetic
59 neuropathy (Naruse 2019). Additionally, a repair process involving demyelination followed by
60 remyelination is involved in wound healing after nerve injury (Ding & Hammarlund 2019). Many
61 factors regulate the differentiation and function of Schwann cells such as several hormonal
62 signaling mediated by members of the nuclear receptor superfamily (Mangelsdorf *et al.* 1995).
63 For instance, thyroid hormones (Barakat-Walter & Kraftsik 2018), androgens (Magnaghi *et al.*
64 2001), progesterone (Schumacher *et al.* 2012) and estrogens (Gu *et al.* 2018) have been
65 reported to improve peripheral nerve regeneration. Glucocorticoid hormones (GC) are also
66 able to promote remyelination and nerve regeneration after injury (Hughes 2002; Morisaki *et*
67 *al.* 2010; Feng & Yuan 2015) although it is not clear if their effects are due to their anti-
68 inflammatory properties or to their endogenous action on SC homeostasis. Conversely, some
69 adverse effects have been reported with antenatal and perinatal GC exposure (Damsted *et al.*
70 2011) such as on the myelination of the auditory nerve in preterm sheep (Rittenschober-Böhm
71 *et al.* 2018). Glucocorticoid actions are mediated by two highly homologous members of the
72 nuclear receptor superfamily, the mineralocorticoid receptor MR, coded by the *Nr3c2* gene
73 also named *Mr* (Viengchareun *et al.* 2007) and the glucocorticoid receptor GR (Oakley &
74 Cidlowski 2013) coded by *Nr3c1* gene, also named *Gr*. Both receptor mRNA were previously
75 reported to be expressed in rodent sciatic nerves and in SC-derived cell lines (Groyer *et al.*
76 2006; Girard *et al.* 2010). MR presents a high affinity for glucocorticoids and is also able to
77 bind specifically the mineralocorticoid hormone aldosterone. As aldosterone plasmatic

78 concentration is 100 times lower than that of glucocorticoids, some mechanisms of hormonal
79 specificity occur in mineralocorticoid-sensitive tissues, mainly in the sodium transporting tight
80 epithelia. In these tissues, aldosterone is mostly known to regulate ion homeostasis (Pearce
81 *et al.* 2022). A mechanism of mineralocorticoid selectivity is the action of the enzyme 11 β HSD2
82 in tight epithelia that metabolized active glucocorticoids into inactive compounds (Farman &
83 Bocchi 2000). In other MR-expressing tissues such as heart, blood vessels, smooth muscles,
84 nervous system, 11 β HSD2 expression is absent or very low indicating that, at least in a non-
85 pathological situation, MR should probably be considered as a high affinity receptor for GC (Le
86 Menuet & Lombès 2014). However, it was reported that in some experimental conditions, the
87 prerequisites for aldosterone signaling, such as 11 β HSD2 expression are present in SC
88 (Groyer *et al.* 2006; Girard *et al.* 2010). GR affinity for GC is around 10 times lower than that
89 of MR. It has been proposed that GR and MR act in balance depending of the concentration
90 of GC which follows circadian variations with a peak after waking and a trough at the beginning
91 of the sleeping period. Altogether, this indicates that concerning glucocorticoid actions, it is
92 important to consider the contributions of both MR and GR receptors. A low concentration of
93 GC such as during the trough of the circadian rhythm is considered to be already sufficient to
94 occupy most of MR receptors while binding to GR is significant only at the daily peak of GC
95 concentration and under stress (de Kloet *et al.* 2005).

96 Because of the major importance of GC hormones regulating stress, circadian rhythm,
97 metabolism, immunity and in affecting all the tissues (Kadmiel & Cidlowski 2013), it is of great
98 value to investigate GC actions in the PNS that have been little studied so far (Madalena &
99 Lerch 2017). We focused here on the role of MR in the PNS. We revealed the expression and
100 functionality of MR in SC in vitro and in vivo and developed a mouse model of SC specific MR
101 knockout, SCMRKO. GR expression in the sciatic nerve was increased in SCMRKO mice
102 indicating a possible compensation by GR after MR loss. No motor behavioral abnormalities
103 were evidenced in this model, however, myelin sheaths of axons larger than 15 μ m in perimeter
104 were enlarged in the sciatic nerves.

106 **Materials and Methods**

107 **Cell culture.** MSC80 (Baron-Van Evercooren *et al.* 1992) cells (a gift from *Institut du Cerveau*
108 (ICM), Inserm U1127, Paris France) were cultured as previously described (Shackleford *et al.*
109 2018). For hormonal treatment and antagonists, cells were plated at 50,000 cells/ wells of 12
110 well plates and changed in serum-free medium after two days. Treatment was performed the
111 following day. Aldosterone, spironolactone, dexamethasone and RU486 (all from Roche) were
112 diluted in ethanol, and added at 1/10,000 final dilution each in culture medium. Primary SC
113 cultures derived from E13.5 mouse dorsal root ganglia (pregnant C57BL/6 dams from Janvier
114 Labs, Le Genest-Saint-Isle, France) that were dissociated in trypsin, plated and grown as
115 previously described (Sundaram *et al.* 2021). Confluent cultures were used to seed 12 well
116 plates at 50,000 cells/wells and treatments were performed as described with MSC80 cells.
117 The proliferation and differentiation medium were free of serum.

118 **Reverse Transcription-quantitative PCR.** RNA from cells and sciatic nerves, the latter
119 homogenized with a bead mill (Fisherbrand, Illkirch, France), were extracted with Trizol
120 reagent (Life Technologies). Reverse Transcriptions were performed with one μg of total RNA
121 (unless stated otherwise). After DNase treatment (Promega), RNA were reverse-transcribed
122 with MMLV reverse transcriptase (Thermofisher) in a 50 μL volume according to the
123 manufacturer instructions. qPCR were performed with 0.7 μL of RT using Sybr Green
124 (Thermofisher) reagent. The primer sequences are listed in Table 1. RT are amplified with a
125 CFX384 Touch Real-Time PCR Detection System (Biorad). Results are the mean of
126 experimental triplicates and were analyzed according to the $\Delta\Delta\text{CT}$ method. For each set of
127 experiments, the normalization gene was determined as the one showing the lowest variations
128 from a series of 10 normalization genes (Sundaram *et al.* 2019).

129 **Animals and behavioral tests.** MR fl/fl animals were generated by Berger *et al.* (Berger *et al.*
130 2006), and were kindly provided by Dr Frédéric Jaisser, Inserm U1138, *Centre de Recherche*
131 *des Cordeliers*, Paris, France. Jackson Laboratory provided the dhhCre animals (FVB(Cg)-
132 Tg(Dhh-cre)1Mejr/J, strain 112929), both lines being previously backcrossed in the C57BL/6J

133 genetic background. This project received the agreement number C750607 and was approved
134 by the animal facility (*Plateforme d'hébergement et d'élevage*, BiomedTech facilities,
135 *Université Paris Cité*), the local ethic comity (Ceea40) and received the number D750607 by
136 the French government. Animals were housed with a 12 h light/dark cycle under constant
137 temperature. Behavioral tests were performed between 10 and 12 AM with groups of littermate
138 males. Four to five mice of both genotypes were reared in the same cage. Animals were tested
139 each month between 2 and 6-month of ages. For the grip strength test (Bioseb, Vitrolles,
140 France), animals were tested on two different days of the same week each month. The highest
141 value of three trials for the forepaws and three trials for the four limbs was recorded. Eventually
142 the averages of the two monthly values were calculated. For rotarod (Orchid Scientific, Dehli,
143 India), mice were also tested at two different days. For each day, each animal was tested twice
144 with interval of at least 30 minutes between passages, and the mean values were recorded
145 (time and distance walked). For automatic locomotor test Locotronic® (Intellibio, Seichamps,
146 France), animals crossed the ladder 3 times, with a 30-minute lag. Two sessions each month
147 were averaged. The values (number of errors, and travel times) of the first trial were ignored,
148 being considered as habituation.

149 **Genomic PCR.** Tissues were lysed at 55°C overnight in buffer containing NaCl 200 mM, SDS
150 5 mM, EDTA 5 mM, Tris 100 mM (pH 8.5), 0.5 mg/ mL proteinase K then spin at 12,000 g.
151 Supernatant were precipitated with isopropanol, spin at 12,000 g, then DNA was solubilized in
152 water. PCR reactions were performed according to the conditions previously described for MR
153 flox allele (Berger *et al.* 2006) and from Jackson laboratories for dhhCre allele. Primers are
154 listed in Table 1.

155 **Immunofluorescence.** Four-month old mouse sciatic nerves were dissected and fixed in
156 paraformaldehyde 4% in PBS at 4°C overnight., incubated in 10 mM citrate ph=6 at 95°C 5
157 minutes for antigen retrieval. Nerves were then incubated in sucrose 20% in OCT (optimal
158 cutting temperature, Thermofisher) in a mold and froze. Twelve µm thick sections were cut
159 with a cryostat and disposed on 3-(triethoxysilyl)propylamine (TESPA)-treated slides. Section

160 were then permeabilized with 0.2% triton X100, 0.1% tween 20, blocked with 2% BSA and 5%
161 donkey serum in PBS tween 0.1%, incubated at 4°C overnight with primary antibodies (rabbit
162 anti-MR Thermofisher PA-95019, 1/100 and goat anti-sox10 R&D AF 2864 1/200 as previously
163 validated (Sundaram *et al.* 2021)) then incubated with secondary antibodies (donkey anti-
164 rabbit Alexa 488 1/2,000 and donkey anti-goat Cy3 1/500, Jackson IR). Nuclei were labeled
165 with Hoescht, slides were mounted in coverslips with fluoromount-G (Thermofisher) and dry
166 overnight. Slides were observed with an Axio Observer inverted microscope (Zeiss). Images
167 were snapped with Zen 3.2 software (Zeiss) and elaborated using the same parameters for
168 each sample. For immunocytochemistry, cells were grown in 8 chamber slides (labTek,
169 Thermo Fisher) in the same conditions described in the cell culture chapter. Cells were then
170 fixed in paraformaldehyde 4% for 15 min, wash and permeabilized for 5 min in 0.2% Triton
171 X100, 0.1% Tween 20, blocked in 5% BSA and Lab-Teks then treated similarly to the nerve
172 sections. GR monoclonal rabbit antibody (D6H2L, Cell Signaling) was used at 1/200 (Delangre
173 *et al.* 2021) .

174

175 **Western blot.**

176 Sciatic nerves were homogenized with a bead mill (FisherBrand) in RIPA buffer containing
177 protease inhibitors (Roche). Thirty µg of protein were loaded and migrated in SDS PAGE 10%
178 acrylamide/bis-acrylamide. Gels were transferred on nitrocellulose membranes and incubated
179 overnight (4°C) with primary antibodies (rabbit anti-MR Thermofisher PA-95019, 1/250 or
180 rabbit anti-GR Cell signaling D6H2L 1/1,000 (Chen *et al.* 2019) and mouse anti- α tubulin
181 Sigma-Aldrich T6074 1/10,000), then with secondary antibodies (goat anti-rabbit IgG Dylight
182 800 and anti-mouse IgG Dylight 680 at 1:10,000 each, from Thermo Scientific) 1 h at room
183 temperature. An Odyssey infrared imaging system (LI-COR, Bad Homburg, Germany) was
184 used to scan membranes. Bands were quantified with Odyssey Application Software version
185 3.0 (LI-COR).

186 **Transmission electron microscopy and g-ratio determination.** Sciatic nerves were fixed in
187 paraformaldehyde 4% glutaraldehyde 25% solution, then stained with osmium tetroxide and
188 embedded in epoxy resin as previously described (Makoukji *et al.* 2011). Ultrathin 50 nm
189 sections were performed and visualized by Transmission Electron Microscope JEOL 1011 in
190 the PIME core facility (*Institut Cochin*, Paris, France). g-ratio was calculated using Image J
191 software dividing the inside perimeter of the myelin sheath by the outside perimeter. Around
192 150 to 200 sheaths by nerve were quantified and the captions were spread over the total
193 surface of the nerve section.

194 **Statistical analysis.** Statistical analyses were conducted using Mann-Whitney test, suitable
195 for non-parametric comparisons of two experimental groups. The g-ratio statistical analyses
196 were performed with student t-test, adapted to compare two groups of values presenting a
197 gaussian distribution.

198

199

200 **Results**

201 **Functional MR and GR signaling in Schwann Cells in vitro**

202 The MSC80 cell line was spontaneously immortalized from mouse sciatic nerve (Baron-Van
203 Evercooren *et al.* 1992) and retained the expression of several myelinating SC-specific
204 markers such as MPZ, PMP22 and Krox20 (Shackleford *et al.* 2018). Expression of MR and
205 GR protein was detected by immunocytochemistry together with the SC specific transcription
206 factor Sox10 (Fig 1A), as well as in Western blot (Fig 1B). Expression of the glucocorticoid
207 target gene *Per1* transactivated by both MR and GR (Le Billan *et al.* 2015) was then used as
208 an index of both receptors functionality in MSC80. Cells were treated for 3 hours in a serum
209 free medium by aldosterone (Aldo), the physiological specific MR ligand, dexamethasone
210 (Dex), a synthetic glucocorticoid that binds only to GR, spironolactone an MR antagonist,
211 RU486 a GR antagonist, then *Per1* expression was measured by RT-qPCR. Both agonists
212 were able to significantly stimulate *Per1* at different levels (Aldo 2-fold stimulation; Dex 8-fold
213 stimulation) expression while antagonists specifically repressed the agonistic effect (Fig 1C).
214 Treatments with each antagonist (Spiro, RU) did not modify *Per1* expression. This indicates
215 that MR and GR are functional in the MSC80 cell line. A time-course experiment under
216 aldosterone treatment showed that *Per1* expression was stimulated after a 2 h treatment and
217 stimulation persisted for 24 h; this timeline being compatible with a transcriptional effect of MR
218 (Fig. 1D). MR and GR expressions were detected in primary Schwann cell cultures (pSC)
219 derived from E13.5 mouse dorsal root ganglia with immunofluorescence, colocalizing with
220 Sox10 (Fig. 1E). This preparation method allows to obtain a very pure SC culture with low
221 fibroblast contaminations compared to SC cultures isolated from sciatic nerve (Sundaram *et*
222 *al.* 2021). Indeed, only few cells are negative for Sox10 as visualized in the merged panel (Fig.
223 1E). The receptor expression levels were then investigated in pSC. Cultures can be maintained
224 either in proliferation or on differentiation phenotype after cAMP treatment. Both *Mr* and *Gr*
225 transcripts were clearly detected (Fig. 1F and 1G) by RT-qPCR, in proliferative and
226 differentiating pSC cultures and the *Mr* expression level appeared to be 10 to 15 times lower

227 than *Gr*, as observed in many tissues (Farman & Bocchi 2000). The qPCR cycle threshold
228 (CT) numbers (Fig. 1H) are indicated to evaluate the scale of the expression level for each
229 gene. The functionality of the receptors in differentiated pSC cultures was assessed measuring
230 the expression of the MR and GR target gene *Fkbp5* (Le Billan *et al.* 2015) under agonists and
231 antagonists treatment. As with MSC80 cells, in primary culture, MR and GR were able to
232 transactivate a target gene in presence of the agonists while the antagonists abolished this
233 effect (Fig. 1G). The lower transactivation potency of MR compared to GR may be due in part
234 to its lower expression level. Altogether, these data show that both glucocorticoid receptors
235 MR and GR are expressed and respond to their ligands in SC-derived cellular models and
236 pSC.

237

238 **Generation of a mouse knockout model for MR in Schwann cells**

239 To better understand MR's role in the peripheral nervous system, MR knockout targeted in SC
240 was performed by breeding the MR flox/flox (MR fl/fl) mice, and the dhhCre mouse line
241 harboring the SC-specific promoter of Desert hedgehog driving the expression of the Cre
242 recombinase cDNA (Zhang *et al.* 2019). Both models were characterized and validated in
243 previous studies (Berger *et al.* 2006; Wu *et al.* 2008; Rickard *et al.* 2012). After two generations,
244 MR fl/fl animals (Control, Ctrl) were crossed to MR fl/fl dhhCre/+ mice (with *Mr* knockout in SC,
245 SCMRKO) and were stably bred (Fig 2A). Sex ratio and genotype repartition were as expected
246 in the breeding, and SCMRKO were viable and healthy. Nerve specific excision of MR in
247 SCMRKO animals was visualized by PCR. For negative controls to test the specificity of the
248 excision DNA from hippocampus (Hip) were used, where myelination is ensured by
249 oligodendrocytes and does not contain SC, as well as liver lobes (LV) which are poorly
250 innervated and highly vascularized (Fig. 2B). Brachial nerve (Nv) DNA was used to visualize
251 the excision. Figure 2B shows PCR products from a control (Ctrl) and an SCMRKO mouse
252 using primers from dhhCre (290 bp) transgene and for the MR fl construct (345 bp) or the
253 excised allele (390 bp) for the 3 sets of DNA (Nv, Hip, Lv). In SCMRKO animals, excision of

254 the MR fl construct is only visible in the brachial nerve DNA. Only the flox allele amplification
255 is found in hippocampus, and liver DNA, the latter indicating no excision in blood vessels and
256 endothelial cells. The expression of *Mr* in sciatic nerves was then assessed by qPCR in Ctrl
257 and SCMRKO mice (Fig. 2C). A significant 50% reduction in MR expression was observed in
258 SCMRKO animals. A total suppression of *Mr* expression and total *Mr* excision in SCMRKO
259 was not expected as sciatic nerves also contain blood vessels composed of smooth muscle
260 cells as well as fibroblasts which express MR (Pruthi *et al.* 2014). As female sex hormones are
261 reported to present an effect on myelination (Schumacher *et al.* 2012; Gu *et al.* 2018) and are
262 secreted cyclically, at this stage only males have been explored.

263

264 **In situ validation of Schwann Cell MR knockout in the sciatic nerve**

265 In order to validate in situ the specificity of MR knockout in SC, immunofluorescence was
266 performed to analyze the co-localization of MR with the SC-specific transcription factor Sox10
267 in sciatic nerve. The labeling obtained in sciatic nerve from 6-month-old Ctrl and SCMRKO
268 mice are shown, respectively (Figs. 3A and B). The negative control incubating the slices with
269 solely secondary antibodies did not show any labeling (Fig. 3C). Zooming (white rectangles)
270 in Ctrl nerve (Fig. 3D) and SCMRKO nerve (Fig. 3E), showed that, despite some background
271 noise in MR labeling especially inside the axons, a clear colocalization of MR with Sox10 is
272 observed in the nuclei of sciatic nerve from Ctrl animals (Fig. 3D, merged panel) while no
273 labeling above background noise is observed for Sox10 positive cells in SCMRKO animals,
274 albeit few cells show some weak, background-like, MR-antibody staining (see grey arrow). To
275 our knowledge, this is the first visualization of MR protein expression in SCs reported to date.
276 Indeed, previous studies in sciatic nerves have detected *Mr* RNA or indirectly aldosterone
277 binding by MR (Groyer *et al.* 2006). These data validate the specificity of SC MR knockout
278 confirming genomic PCR data (Fig. 2B).

279

280 **Functional assessment of MR knockout in Schwann Cells**

281 First, we showed that there was no difference in body weight between Ctrl and SCMRKO
282 animals (Fig. 4A). Several motor behavioral tests were performed with male Ctrl and SCMRKO
283 mice every month from 2 to 6 months of age. In the rotarod test mice are put on an accelerating
284 rotating rod inducing a force motor activity. The time preceding the fall off the rod of the animal
285 is measured (Fig. 4B) and there was no significant effect of the inactivation of MR in SC. Grip
286 strength test allows to measure the maximum strength of a mouse either with its forepaws
287 gripping a rod, either with its four limbs gripping a grid. There was no difference between control
288 and SCMRKO mice for the strength measured with forepaws alone, which revealed also the
289 ability to grasp (Fig. 4C) as well as with the four limbs (Fig. 4D). Motor coordination while
290 walking was tested with the automatic locomotor test (Locotronic®) consisting in the monitoring
291 of the crossing of a horizontal ladder. Neither the number of errors (stumbling between rungs,
292 Fig. 4E) nor the travel time was modified in SCMRKO animals (Fig. 4F). Only the results at 6
293 months are presented as in younger ages the number of errors was low.

294

295 **MR knockout is associated with GR upregulation in sciatic nerves**

296 To further analyze the effect of MR knockout in SC, the expression levels of several SC specific
297 genes were measured in Ctrl and SCMRKO sciatic nerves from 3-month old male mice by
298 qPCR (Fig. 5). *Krox20* (or *Egr2*) encodes for a transcription factor specific of myelinating SC
299 while *p75NTR* encodes for the receptor for neurotrophins that characterized the non-
300 myelinating SC. There were no significant differences between groups for the mRNA
301 expression of this genes (Fig. 5A and 5B). mRNA expressions of *Mpz*, *Pmp22* and *Mbp* genes,
302 all coding for structural proteins of the myelin sheath were also not significantly modified in
303 SCMRKO (Fig. 5C, D and E). Besides, there is no clear trend on MPZ protein quantity
304 compared between groups (Fig. 5F) apart for a larger variability among individuals for
305 SCMRKO sciatic nerves. Concerning glucocorticoid signaling genes in the sciatic nerve, MR

306 and GR target genes *Sgk* (Fig. 6A) and *Per1* (Fig. 6B) transcript expressions are not
307 significantly modified by the knockout of *Mr* in SC while a significant 35% increase of *Gr* mRNA
308 expression was measured in SCMRKO (Fig. 6C). The protein level of MR and GR in SCMRKO
309 mouse sciatic nerve were examined by Western blot (Fig.6 D and E). As found for *Mr*
310 transcripts, MR quantity is decreased by around 30% in SCMRKO ($p<0.05$) compared to
311 controls, reflecting *Mr* excision in the SC (Fig. 6D). Concerning GR, a significant 50% increase
312 ($p<0.05$; of note around 35% increase, without outlier point in SCMRKO nerve, $p=0.0258$, not
313 shown) of GR protein amount was measured in SCMRKO sciatic nerve lysates, consistent with
314 the results obtained with *Gr* transcripts (Fig. 6E). As *Mr* knockout in SC is associated with an
315 increase GR protein amount in the sciatic nerve, it would be difficult to separate the effects of
316 MR from that of GR with this animal model.

317

318 **MR inactivation is associated with larger myelin sheaths around large caliber axons**

319 Subsequently, morphological examination of transversal sciatic nerve section was performed
320 with transmission electron microscopy. Sections were from both nerves of six animals that
321 underwent the locomotor tests (Fig. 7A and B) at 6 months of age. Myelin (M) sheaths formed
322 dark layers around axons. In some places the presence of SC cellular bodies and nuclei are
323 visible. Remak Bundles (RB) are composed of unmyelinated SC surrounding several small
324 caliber axons corresponding to sensitive fibers. Thickness of the myelin sheath compared to
325 the diameter of the axon was assessed by calculating the g-ratio, which corresponds to the
326 inner perimeter of the myelin sheath divided by its outer perimeter, therefore g-ratio is always
327 less than 1. Determining the g-ratio value showed that it is significantly smaller (0.699) in
328 SCMRKO animals, thus corresponding to larger myelin sheaths compared to control (0.713;
329 $p<0.0001$, Fig. 7C). To have a better understanding of this difference, g-ratio distribution was
330 examined as a function of the values of axon perimeters (Fig. 7D). There was no difference
331 between groups for axon smaller than 15 μm in perimeter. Besides, a significant decrease of
332 g-ratio, corresponding to myelin sheath enlargement, was found in SCMRKO axons between

333 15 to 25 μm of axon perimeter (15 to 20 μm : Ctrl g-ratio=0.724 vs 0.690 for SCMRKO,
334 $p<0.0001$; 20 to 25 μm , Ctrl g-ratio=0.740 vs 0.708 for SCMRKO, $p<0.001$, $>25\mu\text{m}$ Ctrl g-
335 ratio=0.775 vs 0.745 for SCMRKO; $p<0.01$ with student t-test). As a whole, for axon perimeters
336 larger than 15 μm , g-ratios decrease by around 4.5% in SCMRKO animals. Scatter plot of g-
337 ratio values further revealed the lower g-ratio for the SCMRKO sheaths associated with a less
338 marked regression curve slope (Fig. 5E). Apart for sheath thickness, there were no obvious
339 morphological differences between the two groups.

340

341 **Discussion.**

342 The study of glucocorticoid hormone actions, putting aside their anti-inflammatory properties,
343 is a blind spot in the scientific literature on the peripheral nervous system, especially
344 concerning Schwann cells (Groyer *et al.* 2006; Girard *et al.* 2010). Considering the crucial
345 importance of glucocorticoid hormones in regulating the functions of most tissues in mammals,
346 the investigation of their role in the PNS is of great interest. We demonstrated here that both
347 receptors, MR and GR are expressed and functional in Schwann cells. We then focused on
348 the function of MR because it is a high affinity receptor for glucocorticoids. The specific deletion
349 of *Mr* gene in mouse Schwann cells is associated with an increase of myelin sheath thickness
350 for large caliber axons but with no modification of locomotor behavior at 6 months of age. It is
351 noteworthy that, for the sake of reducing the number of animals used, the same group of mice
352 has performed all tests at different ages and animals with no training may have performed
353 differently in some tests after the age of two months. Additionally, some differences may have
354 emerged after 6 months of age. An issue not addressed in this work was the potential effect of
355 *Mr* deletion in unmyelinating SC that interact with low diameter axons of sensitive fibers,
356 forming the Remak bundles. However no major motor behavior alterations were noted in
357 SCMRKO animals, as expected in the case of alterations of sensitive fiber functions that can

358 cause neuropathic pain (Gross & Üçeyler 2020). This indicates that a major role of MR in
359 unmyelinating SC is not likely to be revealed by this model.

360 Importantly, *Mr* excision is also associated with an increase of *Gr* transcripts and GR protein
361 amounts in the sciatic nerve. This raises the question whether the modification of myelin
362 thickness observed in SCMRKO sciatic nerves is due to the absence of MR in Schwann cells
363 or to the overabundance of GR. It is also possible that the increase of GR quantity is a
364 compensatory mechanism masking some consequences of MR absence. Interestingly,
365 increase of GR quantity after MR excision was previously reported with the knockout of MR in
366 the mouse hippocampus (Oakley *et al.* 2021). All this hints to the fact that MR and GR actions
367 are combinatorial in SC.

368 In the first decades following MR characterization, it was thought that its expression was
369 restricted to the sodium transporting tight epithelia, the hippocampus in the CNS and the
370 cardiovascular system, while GR expression was described as being ubiquitous (Funder
371 1996). Although sometimes hard to put in evidence due to a lower expression level compared
372 to GR and some technical difficulties in immunodetection, it appears now that MR expression
373 could be widespread. Indeed, MR physiological importance is now well established in, for
374 instance, skin (Sevilla & Pérez 2018), white (Infante *et al.* 2019) and brown (Kuhn *et al.* 2018)
375 adipocytes as well as in eye tissues (Canonica *et al.* 2021). Recently several studies focused
376 also on the analysis of the role of MR in skeletal muscle (Hauck *et al.* 2019; Hulse *et al.* 2022).
377 Along this line, a locomotor MR and GR axis encompassing motor neuron (Kretz *et al.* 2001),
378 Schwann cell and skeletal muscle that remains to be characterized may be hypothesized. Of
379 note, the clinical relevance of MR in skeletal muscle is illustrated by the development of new
380 therapeutic strategies involving the use of MR antagonists to treat Duchenne muscular
381 dystrophy (Howard *et al.* 2022).

382 Because MR excision in Schwann cells resulted in an increase of GR abundance, the role of
383 MR in peripheral myelination may not be understood without analyzing in parallel the role of
384 GR. Interestingly, MR and GR target gene *Sgk1* total knockout in mouse resulted in a

385 decreased g-ratio of the same magnitude than in SCMRKO animals, and suggested that SGK1
386 regulates myelination by phosphorylating NDRG1 (Heller *et al.* 2014). Moreover, it has been
387 recently proposed that SGK may be a molecular switch for glial regeneration after injury in the
388 PNS (Okura *et al.* 2022). This further highlight a potential involvement of glucocorticoid
389 signaling in peripheral myelination.

390 In some tissues, MR overactivation seems to be associated with pathological states linked with
391 inflammation such as in the cardiovascular and immune systems. The knockout of MR
392 specifically in cardiomyocytes (Rickard *et al.* 2012), myeloid cells (Li *et al.* 2014), macrophages
393 (Bienvenu *et al.* 2012), vascular smooth muscle cells (Pruthi *et al.* 2014) and endothelial cells
394 (Jia *et al.* 2015) result in a better resistance to experimentally induced injury. Eventually, that
395 may be also tested in the SCMRKO model using, for instance, sciatic nerve crush experiments.
396 Along this line, MR antagonists are now widely used in medicine for the treatment of
397 cardiovascular system pathologies and is currently under development for other pathologies
398 (Epstein 2015). That raises the question of the exact role of MR in normal physiology in these
399 organs, and how to reveal it in term of protocol in animal experimentation. For instance, it may
400 be considered that rodents in animal facilities are very well fed, poorly exercised and kept in
401 thermal neutrality. These conditions may not be optimal to reveal the potential benefits of MR
402 signaling. On the other hand, non-pathological actions of MR are better understood principally
403 in aldosterone-sensitive sodium transporting epithelia (Epstein *et al.* 2022) and in limbic
404 system neurons (Joëls & de Kloet 2017). For the latter, it is now clear that study of MR and
405 GR actions cannot be dissociated (Oakley *et al.* 2021).

406 In conclusion, glucocorticoid hormones present widespread actions in vertebrates and their
407 roles in the peripheral nervous system are not well understood, most particularly the
408 contribution of their receptors MR and GR. It is important to gain more insights in this field of
409 research as glucocorticoid compounds are among the most prescribed drugs (Martins & de
410 Castro 2021) and glucocorticoid hormones are key mediators in stress, immunity and

411 metabolism (Oakley & Cidlowski 2013) whose dysregulations are damaging for the peripheral
412 nervous system and are central in pathologies induced by modern lifestyle.

413

414

415

416

417 **Acknowledgements**

418 We are indebted to Dr. Frédéric Jaisser; Inserm U1138, *Centre de Recherche des Cordeliers*
419 to provide the MR fl/fl mice originally obtained by Berger et al (Berger *et al.* 2006). We thank
420 UMS BioMedTech facilities, *Campus Saint Germain des Près, Université Paris Cité*, for
421 providing access to the molecular and cellular biology platform Cyto2BM, and also for the
422 housing and breeding of the mice. We are particularly indebted with Claire Mader, head of the
423 animal facility, for helping to set up the project authorization request and Isis Blanchard for her
424 expertise with the locomotor test devices. We are grateful to the electron microscopy platform,
425 *Université Paris Cité, Institut Cochin* and to its director Alain Schmitt for the nerve ultrathin
426 sections and their imaging. We thank Dr. Venkat Krishan Sundaram for providing the RT
427 reactions used in Fig. 1F and 1G, and Céline Dargenet-Becker for the primary Schwann cell
428 culture used for immunofluorescence in Fig 1E.

429 **Fundings**

430 This work was support with recurrent funding from INSERM and *Université Paris Cité*. AGM
431 was recipient from a fellowship from the *Fundación Universidad de Burgos*, under the
432 *Viveuropa* European Union program and *Castilla y León* Regional Government, Spain.

433 **Author Contributions**

434 DLM and CM designed the study. DLM wrote the first draft of the manuscript, performed the
435 experiments, and calculated the g-ratio on TEM images. AGM contributed to the writing of the
436 manuscript, the preparation of electron microscopy samples with VSC and together with AE,
437 performed the behavioral test, qPCR experiments, Western blot experiments and set up the
438 immunofluorescence conditions. RD, VSC, AdSR, REK realized qPCR experiments, Western
439 blot immunocytochemistry and further help to the setting up of the immunofluorescence

440 experiments. All authors read and amended the manuscript as well as agreed with its final
441 content.

442

443 **Declaration of interest:** None

444

445

446 **References**

447

448 Barakat-Walter I & Kraftsik R 2018 Stimulating effect of thyroid hormones in peripheral nerve
449 regeneration: research history and future direction toward clinical therapy. *Neural*
450 *Regeneration Research* 13 599–608. (<https://doi.org/10.4103/1673-5374.230274>)

451 Baron-Van Evercooren A, Gansmuller A, Duhamel E, Pascal F & Gumpel M 1992 Repair of a
452 myelin lesion by Schwann cells transplanted in the adult mouse spinal cord. *Journal of*
453 *Neuroimmunology* 40 235–242. ([https://doi.org/10.1016/0165-5728\(92\)90139-c](https://doi.org/10.1016/0165-5728(92)90139-c))

454 Berger S, Wolfer DP, Selbach O, Alter H, Erdmann G, Reichardt HM, Chepkova AN, Welzl H,
455 Haas HL, Lipp H-P & Schütz G 2006 Loss of the limbic mineralocorticoid receptor impairs
456 behavioral plasticity. *Proceedings of the National Academy of Sciences of the United States*
457 *of America* 103 195–200. (<https://doi.org/10.1073/pnas.0503878102>)

458 Bienvenu LA, Morgan J, Rickard AJ, Tesch GH, Cranston GA, Fletcher EK, Delbridge LMD &
459 Young MJ 2012 Macrophage mineralocorticoid receptor signaling plays a key role in
460 aldosterone-independent cardiac fibrosis. *Endocrinology* 153 3416–3425.
461 (<https://doi.org/10.1210/en.2011-2098>)

462 Boullerne AI 2016 The history of myelin. *Experimental Neurology* 283 431–445.
463 (<https://doi.org/10.1016/j.expneurol.2016.06.005>)

464 Canonica J, Zhao M, Favez T, Gelizé E, Jonet L, Kowalczyk L, Guegan J, Le Menuet D,
465 Viengchareun S, Lombès M, Pussard E, Arsenijevic Y & Behar-Cohen F 2021 Pathogenic
466 Effects of Mineralocorticoid Pathway Activation in Retinal Pigment Epithelium. *International*
467 *Journal of Molecular Sciences* 22 9618. (<https://doi.org/10.3390/ijms22179618>)

468 Chen H, Amazit L, Lombès M & Le Menuet D 2019 Crosstalk Between Glucocorticoid Receptor
469 and Early-growth Response Protein 1 Accounts for Repression of Brain-derived Neurotrophic
470 Factor Transcript 4 Expression. *Neuroscience* 399 12–27.
471 (<https://doi.org/10.1016/j.neuroscience.2018.12.012>)

472 Damsted SK, Born AP, Paulson OB & Uldall P 2011 Exogenous glucocorticoids and adverse
473 cerebral effects in children. *European Journal of Paediatric Neurology: EJPN: Official Journal*
474 *of the European Paediatric Neurology Society* 15 465–477.
475 (<https://doi.org/10.1016/j.ejpn.2011.05.002>)

476 Delangre E, Liu J, Tolu S, Maouche K, Armanet M, Cattan P, Pommier G, Bailbé D & Movassat
477 J 2021 Underlying mechanisms of glucocorticoid-induced β -cell death and dysfunction: a new
478 role for glycogen synthase kinase 3. *Cell Death & Disease* 12 1136.
479 (<https://doi.org/10.1038/s41419-021-04419-8>)

480 Ding C & Hammarlund M 2019 Mechanisms of injury-induced axon degeneration. *Current*
481 *Opinion in Neurobiology* 57 171–178. (<https://doi.org/10.1016/j.conb.2019.03.006>)

482 Epstein M 2015 Reduction of cardiovascular risk in chronic kidney disease by mineralocorticoid
483 receptor antagonism. *The Lancet. Diabetes & Endocrinology* 3 993–1003.
484 ([https://doi.org/10.1016/S2213-8587\(15\)00289-2](https://doi.org/10.1016/S2213-8587(15)00289-2))

485 Epstein M, Kovesdy CP, Clase CM, Sood MM & Pecoits-Filho R 2022 Aldosterone,
486 Mineralocorticoid Receptor Activation, and CKD: A Review of Evolving Treatment Paradigms.
487 *American Journal of Kidney Diseases: The Official Journal of the National Kidney Foundation*
488 S0272-6386(22)00744-2. (<https://doi.org/10.1053/j.ajkd.2022.04.016>)

489 Farman N & Bocchi B 2000 Mineralocorticoid selectivity: molecular and cellular aspects.
490 *Kidney International* 57 1364–1369. (<https://doi.org/10.1046/j.1523-1755.2000.00976.x>)

491 Feng X & Yuan W 2015 Dexamethasone enhanced functional recovery after sciatic nerve
492 crush injury in rats. *BioMed Research International* 2015 627923.
493 (<https://doi.org/10.1155/2015/627923>)

494 Funder JW 1996 Mineralocorticoid receptors and glucocorticoid receptors. *Clinical*
495 *Endocrinology* 45 651–656. (<https://doi.org/10.1046/j.1365-2265.1996.8540862.x>)

496 Girard C, Eychenne B, Schweizer-Groyer G & Cadepond F 2010 Mineralocorticoid and
497 glucocorticoid receptors in sciatic nerve function and regeneration. *The Journal of Steroid*
498 *Biochemistry and Molecular Biology* 122 149–158.
499 (<https://doi.org/10.1016/j.jsbmb.2010.07.005>)

500 Gross F & Üçeyler N 2020 Mechanisms of small nerve fiber pathology. *Neuroscience Letters*
501 737 135316. (<https://doi.org/10.1016/j.neulet.2020.135316>)

502 Groyer G, Eychenne B, Girard C, Rajkowski K, Schumacher M & Cadepond F 2006 Expression
503 and functional state of the corticosteroid receptors and 11 beta-hydroxysteroid dehydrogenase
504 type 2 in Schwann cells. *Endocrinology* 147 4339–4350. (<https://doi.org/10.1210/en.2005-1625>)

506 Gu Y, Wu Y, Su W, Xing L, Shen Y, He X, Li L, Yuan Y, Tang X & Chen G 2018 17 β -Estradiol
507 Enhances Schwann Cell Differentiation via the ER β -ERK1/2 Signaling Pathway and Promotes
508 Remyelination in Injured Sciatic Nerves. *Frontiers in Pharmacology* 9 1026.
509 (<https://doi.org/10.3389/fphar.2018.01026>)

510 Hauck JS, Howard ZM, Lowe J, Rastogi N, Pico MG, Swager SA, Petrosino JM, Gomez-
511 Sanchez CE, Gomez-Sanchez EP, Accornero F & Rafael-Fortney JA 2019 Mineralocorticoid
512 Receptor Signaling Contributes to Normal Muscle Repair After Acute Injury. *Frontiers in*
513 *Physiology* 10 1324. (<https://doi.org/10.3389/fphys.2019.01324>)

514 Heller BA, Ghidinelli M, Voelkl J, Einheber S, Smith R, Grund E, Morahan G, Chandler D,
515 Kalaydjieva L, Giancotti F, King RH, Fejes-Toth AN, Fejes-Toth G, Feltri ML, Lang F & Salzer
516 JL. 2014 Functionally distinct PI 3-kinase pathways regulate myelination in the peripheral
517 nervous system. *The Journal of Cell Biology* 204 1219–1236.
518 (<https://doi.org/10.1083/jcb.201307057>)

519 Higuchi Y & Takashima H 2022 Clinical genetics of Charcot-Marie-Tooth disease. *Journal of*
520 *Human Genetics*. (<https://doi.org/10.1038/s10038-022-01031-2>)

521 Howard ZM, Gomatam CK, Piepho AB & Rafael-Fortney JA 2022 Mineralocorticoid Receptor
522 Signaling in the Inflammatory Skeletal Muscle Microenvironments of Muscular Dystrophy and
523 Acute Injury. *Frontiers in Pharmacology* 13 942660.
524 (<https://doi.org/10.3389/fphar.2022.942660>)

525 Hughes R a. C 2002 Systematic reviews of treatment for inflammatory demyelinating
526 neuropathy. *Journal of Anatomy* 200 331–339. (<https://doi.org/10.1046/j.1469-7580.2002.00041.x>)

528 Hulse JL, Habibi J, Igbekele AE, Zhang B, Li J, Whaley-Connell A, Sowers JR & Jia G 2022
529 Mineralocorticoid receptors mediates diet - induced lipid infiltration of skeletal muscle and
530 insulin resistance. *Endocrinology* bqac145. (<https://doi.org/10.1210/endo/bqac145>)

531 Infante M, Armani A, Marzolla V, Fabbri A & Caprio M 2019 Adipocyte Mineralocorticoid
532 Receptor. *Vitamins and Hormones* 109 189–209. (<https://doi.org/10.1016/bs.vh.2018.10.005>)

533 Jia G, Habibi J, DeMarco VG, Martinez-Lemus LA, Ma L, Whaley-Connell AT, Aroor AR,
534 Domeier TL, Zhu Y, Meininger GA, Mueller KB, Jaffe IZ & Sowers JR 2015 Endothelial
535 Mineralocorticoid Receptor Deletion Prevents Diet-Induced Cardiac Diastolic Dysfunction in
536 Females. *Hypertension* (Dallas, Tex.: 1979) 66 1159–1167.
537 (<https://doi.org/10.1161/HYPERTENSIONAHA.115.06015>)

538 Joëls M & de Kloet ER 2017 30 YEARS OF THE MINERALOCORTICOID RECEPTOR: The
539 brain mineralocorticoid receptor: a saga in three episodes. *The Journal of Endocrinology* 234
540 T49–T66. (<https://doi.org/10.1530/JOE-16-0660>)

541 Kadmiel M & Cidlowski JA 2013 Glucocorticoid receptor signaling in health and disease.
542 *Trends in Pharmacological Sciences* 34 518–530. (<https://doi.org/10.1016/j.tips.2013.07.003>)

543 de Kloet ER, Joëls M & Holsboer F 2005 Stress and the brain: from adaptation to disease.
544 *Nature Reviews. Neuroscience* 6 463–475. (<https://doi.org/10.1038/nrn1683>)

545 Kretz O, Schmid W, Berger S & Gass P 2001 The mineralocorticoid receptor expression in the
546 mouse CNS is conserved during development. *Neuroreport* 12 1133–1137.
547 (<https://doi.org/10.1097/00001756-200105080-00017>)

548 Kuhn E, Lamribet K, Viengchareun S, Le Menuet D, Fève B & Lombès M 2018 UCP1
549 transrepression in Brown Fat in vivo and mineralocorticoid receptor anti-thermogenic effects.
550 *Annales d'Endocrinologie*. (<https://doi.org/10.1016/j.ando.2018.04.018>)

551 Le Billan F, Khan JA, Lamribet K, Viengchareun S, Bouligand J, Fagart J & Lombès M 2015
552 Cistrome of the aldosterone-activated mineralocorticoid receptor in human renal cells. *FASEB*
553 *Journal: Official Publication of the Federation of American Societies for Experimental Biology*
554 29 3977–3989. (<https://doi.org/10.1096/fj.15-274266>)

555 Le Menuet D & Lombès M 2014 The neuronal mineralocorticoid receptor: from cell survival to
556 neurogenesis. *Steroids* 91 11–19. (<https://doi.org/10.1016/j.steroids.2014.05.018>)

557 Li C, Zhang YY, Frieler RA, Zheng XJ, Zhang WC, Sun XN, Yang QZ, Ma SM, Huang B, Berger
558 S, Wang W, Wu Y, Yu Y, Duan SZ & Mortensen RM 2014 Myeloid mineralocorticoid receptor
559 deficiency inhibits aortic constriction-induced cardiac hypertrophy in mice. *PloS One* 9
560 e110950. (<https://doi.org/10.1371/journal.pone.0110950>)

561 Madalena KM & Lerch JK 2017 The Effect of Glucocorticoid and Glucocorticoid Receptor
562 Interactions on Brain, Spinal Cord, and Glial Cell Plasticity. *Neural Plasticity* 2017 8640970.
563 (<https://doi.org/10.1155/2017/8640970>)

564 Magnaghi V, Cavarretta I, Galbiati M, Martini L & Melcangi RC 2001 Neuroactive steroids and
565 peripheral myelin proteins. *Brain Research. Brain Research Reviews* 37 360–371.
566 ([https://doi.org/10.1016/s0165-0173\(01\)00140-0](https://doi.org/10.1016/s0165-0173(01)00140-0))

567 Makoukji J, Shackleford G, Meffre D, Grenier J, Liere P, Lobaccaro J-MA, Schumacher M &
568 Massaad C 2011 Interplay between LXR and Wnt/ β -catenin signaling in the negative regulation
569 of peripheral myelin genes by oxysterols. *The Journal of Neuroscience: The Official Journal of*

570 the Society for Neuroscience 31 9620–9629. (<https://doi.org/10.1523/JNEUROSCI.0761->
571 11.2011)

572 Mangelsdorf DJ, Thummel C, Beato M, Herrlich P, Schütz G, Umesono K, Blumberg B, Kastner
573 P, Mark M, Chambon P & Evans RM 1995 The nuclear receptor superfamily: the second
574 decade. *Cell* 83 835–839. ([https://doi.org/10.1016/0092-8674\(95\)90199-x](https://doi.org/10.1016/0092-8674(95)90199-x))

575 Martins CS & de Castro M 2021 Generalized and tissue specific glucocorticoid resistance.
576 *Molecular and Cellular Endocrinology* 530 111277.
577 (<https://doi.org/10.1016/j.mce.2021.111277>)

578 Morisaki S, Nishi M, Fujiwara H, Oda R, Kawata M & Kubo T 2010 Endogenous glucocorticoids
579 improve myelination via Schwann cells after peripheral nerve injury: An in vivo study using a
580 crush injury model. *Glia* 58 954–963. (<https://doi.org/10.1002/glia.20977>)

581 Naruse K 2019 Schwann Cells as Crucial Players in Diabetic Neuropathy. *Advances in*
582 *Experimental Medicine and Biology* 1190 345–356. ([https://doi.org/10.1007/978-981-32-9636-](https://doi.org/10.1007/978-981-32-9636-7_22)
583 7_22)

584 Oakley RH & Cidlowski JA 2013 The biology of the glucocorticoid receptor: new signaling
585 mechanisms in health and disease. *The Journal of Allergy and Clinical Immunology* 132 1033–
586 1044. (<https://doi.org/10.1016/j.jaci.2013.09.007>)

587 Oakley RH, Whirledge SD, Petrillo MG, Riddick NV, Xu X, Moy SS & Cidlowski JA 2021
588 Combinatorial actions of glucocorticoid and mineralocorticoid stress hormone receptors are
589 required for preventing neurodegeneration of the mouse hippocampus. *Neurobiology of Stress*
590 15 100369. (<https://doi.org/10.1016/j.ynstr.2021.100369>)

591 Okura A, Inoue K, Sakuma E, Takase H, Ueki T & Mase M 2022 SGK1 in Schwann cells is a
592 potential molecular switch involved in axonal and glial regeneration during peripheral nerve
593 injury. *Biochemical and Biophysical Research Communications* 607 158–165.
594 (<https://doi.org/10.1016/j.bbrc.2022.03.123>)

595 Pearce D, Manis AD, Nesterov V & Korbmacher C 2022 Regulation of distal tubule sodium
596 transport: mechanisms and roles in homeostasis and pathophysiology. *Pflugers Archiv:*
597 *European Journal of Physiology* 474 869–884. (<https://doi.org/10.1007/s00424-022-02732-5>)

598 Pruthi D, McCurley A, Aronovitz M, Galayda C, Karumanchi SA & Jaffe IZ 2014 Aldosterone
599 promotes vascular remodeling by direct effects on smooth muscle cell mineralocorticoid
600 receptors. *Arteriosclerosis, Thrombosis, and Vascular Biology* 34 355–364.
601 (<https://doi.org/10.1161/ATVBAHA.113.302854>)

602 Rickard AJ, Morgan J, Bienvenu LA, Fletcher EK, Cranston GA, Shen JZ, Reichelt ME,
603 Delbridge LM & Young MJ 2012 Cardiomyocyte mineralocorticoid receptors are essential for
604 deoxycorticosterone/salt-mediated inflammation and cardiac fibrosis. *Hypertension (Dallas,*
605 *Tex.: 1979)* 60 1443–1450. (<https://doi.org/10.1161/HYPERTENSIONAHA.112.203158>)

606 Rittenschober-Böhm J, Rodger J, Jobe AH, Kallapur SG, Doherty DA, Kramer BW, Payne MS,
607 Archer M, Rittenschober C, Newnham JP, Miura Y, Berger A, Matthews SG & Kemp MW 2018
608 Antenatal Corticosteroid Exposure Disrupts Myelination in the Auditory Nerve of Preterm
609 Sheep. *Neonatology* 114 62–68. (<https://doi.org/10.1159/000487914>)

610 Salzer JL 2012 Axonal regulation of Schwann cell ensheathment and myelination. *Journal of*
611 *the Peripheral Nervous System: JPNS* 17 Suppl 3 14–19. ([https://doi.org/j.1529-](https://doi.org/j.1529-8027.2012.00425.x)
612 [8027.2012.00425.x](https://doi.org/j.1529-8027.2012.00425.x))

613 Schumacher M, Hussain R, Gago N, Oudinet J-P, Mattern C & Ghoumari AM 2012
614 Progesterone synthesis in the nervous system: implications for myelination and myelin repair.
615 *Frontiers in Neuroscience* 6 10. (<https://doi.org/fnins.2012.00010>)

616 Sevilla LM & Pérez P 2018 Roles of the Glucocorticoid and Mineralocorticoid Receptors in
617 Skin Pathophysiology. *International Journal of Molecular Sciences* 19 E1906.
618 (<https://doi.org/ijms19071906>)

619 Shackleford G, Sampathkumar NK, Hichor M, Weill L, Meffre D, Juricek L, Laurendeau I,
620 Chevallier A, Ortonne N, Larousserie F, Herbin M, Bièche I, Coumoul X, Beraneck M, Baulieu
621 EE, Charbonnier F, Pasmant E & Massaad C. 2018 Involvement of Aryl hydrocarbon receptor
622 in myelination and in human nerve sheath tumorigenesis. *Proceedings of the National*
623 *Academy of Sciences of the United States of America* 115 E1319–E1328.
624 (<https://doi.org/10.1073/pnas.1715999115>)

625 Shahrizaila N, Lehmann HC & Kuwabara S 2021 Guillain-Barré syndrome. *Lancet* (London,
626 England) 397 1214–1228. ([https://doi.org/10.1016/S0140-6736\(21\)00517-1](https://doi.org/10.1016/S0140-6736(21)00517-1))

627 Sundaram VK, Sampathkumar NK, Massaad C & Grenier J 2019 Optimal use of statistical
628 methods to validate reference gene stability in longitudinal studies. *PloS One* 14 e0219440.
629 (<https://doi.org/10.1371/journal.pone.0219440>)

630 Sundaram VK, El Jalkh T, Barakat R, Fernandez CJI, Massaad C & Grenier J 2021 Retracing
631 Schwann Cell Developmental Transitions in Embryonic Dissociated DRG/Schwann Cell
632 Cocultures in Mice. *Frontiers in Cellular Neuroscience* 15 590537.
633 (<https://doi.org/10.3389/fncel.2021.590537>)

634 Viengchareun S, Le Menuet D, Martinerie L, Munier M, Pascual-Le Tallec L & Lombès M 2007
635 The mineralocorticoid receptor: insights into its molecular and (patho)physiological biology.
636 *Nuclear Receptor Signaling* 5 e012. (<https://doi.org/10.1621/nrs.05012>)

637 Wu J, Williams JP, Rizvi TA, Kordich JJ, Witte D, Meijer D, Stemmer-Rachamimov AO,
638 Cancelas JA & Ratner N 2008 Plexiform and dermal neurofibromas and pigmentation are
639 caused by Nf1 loss in desert hedgehog-expressing cells. *Cancer Cell* 13 105–116.
640 (<https://doi.org/10.1016/j.ccr.2007.12.027>)

641 Zhang S-J, Li X-X, Yu Y, Chiu AP, Lo LH, To JC, Rowlands DK & Keng VW 2019 Schwann
642 cell-specific PTEN and EGFR dysfunctions affect neuromuscular junction development by
643 impairing Agrin signaling and autophagy. *Biochemical and Biophysical Research*
644 *Communications* 515 50–56. (<https://doi.org/10.1016/j.bbrc.2019.05.014>)

646 **Figure legends**

647 **Figure 1. MR and GR are expressed and functional in primary Schwann cell cultures. A)**
648 Immunocytochemistry on MR (green), Sox10 (red) and GR (green) in MSC80 cells. MR and
649 Sox10 pictures are in the same field. Ctrl-, negative control: merged field with Hoescht (blue)
650 and secondary antibodies only; white bar is 10 μ m. B) MR and GR proteins are detected by
651 western blot in lysates from Schwann cell derived MSC80 cells (untreated cells in duplicate).
652 C) Hormonal treatment of MSC80 cells; VEH, vehicle (ethanol); Aldo, aldosterone 10^{-8} M; Aldo
653 Spiro: Aldosterone 10^{-8} M and Spironolactone 10^{-6} M; DEX: dexamethasone 10^{-7} M; DEX RU:
654 dexamethasone 10^{-7} M and RU486 (mifepristone) 10^{-6} M; Spiro: Spironolactone 10^{-6} M; and
655 RU: RU486 10^{-6} M. *Per1* expression was measured by RT-qPCR using $\Delta\Delta$ CT with *Mrlp10*
656 normalization gene (n=6 wells/treatment). Statistical analysis, Mann Whitney test; ** vs Veh
657 $p < 0.01$; # vs Aldo $p < 0.05$; \$\$ vs DEX $p < 0.01$. D) MSC80 were treated with Veh and Aldo for 2
658 hours (2h), 3 hours (3h) and 24 hours (24h), and *Per1* expression was analyzed by the $\Delta\Delta$ CT
659 method using *Mrlp10* normalization gene (n=6 wells/condition). Mann Whitney test; ** $p < 0.01$
660 vs VEH 2h; \$\$ $p < 0.01$ vs VEH 3h and ## $p < 0.05$ vs VEH 24 hours. E) Immunocytochemistry
661 on GR (green), Sox10 (red) and MR (green) in Primary SC cultures. MR and Sox10 and
662 merged are from the same field; white bar 10 μ m. White star (*), MR positive Sox10 negative
663 cell. Ctrl-, negative control: merged field with Hoescht (blue) and secondary antibodies only;
664 white bar is 10 μ m F, G, H) Analysis of MR and GR signaling in primary Schwann cell cultures
665 (pSC, bright field mid-center) from mouse E13.5 embryo dorsal root ganglia. *Mr* and *Gr* mRNA
666 expression are assessed in Proliferative (Prol) and Differentiating (Dif) pSC. H) MR and GR
667 qPCR determined CT (from 500 ng RNA RT) are reported from 2 individual cultures in Prol or
668 Dif culture conditions. F) and G) qPCR amplification of *Mr* and *Gr*, respectively, on the same
669 samples normalized by $\Delta\Delta$ CT method with *Sdha* and *Mrlp10* gene expression (n=3
670 wells/treatment for each graphs). *Mr* expression level is around one tenth of *Gr* expression. G)
671 Expression of MR and GR target gene *Fkbp5* in differentiating primary Schwann cell culture
672 measure by RT-qPCR and normalized by $\Delta\Delta$ CT method with *Hsp60* expression (N=6

673 wells/treatment). VEH, vehicle (ethanol); Aldo, aldosterone 10^{-8} M; Aldo Spiro, aldosterone 10^{-8}
674 M + Spironolactone 10^{-6} M; DEX, dexamethasone 10^{-7} M; DEX RU, dexamethasone 10^{-7} M
675 + RU486 10^{-6} M. Mann Whitney test; **, $p < 0.01$ vs Veh; ###, $p < 0.0001$ vs Aldo; \$\$, $p < 0.01$ vs
676 DEX; error bars +/- SD

677 **Figure 2. Generation of SCMRKO mice.** MRSCKO mice were generated by crossing the MR
678 flox/flox (MR fl/fl) mouse strain with the dhhCre strain, generating heterozygous animals (MR
679 flox/+) that are subsequently backcrossed to obtain MR fl/fl and MR fl/fl/ dhhCre animals to
680 fund the breeding colony (Fig 2A). Illustrations are from BioRender free version. B) Gel
681 electrophoresis of PCR products amplified on genomic DNA from brachial nerve (Nv),
682 hippocampus (Hip), Liver (Lv) for dhhCre transgene of a SCMRKO mouse and a control (Ctrl)
683 mouse. Left gel; MW, molecular weight; dhhCre transgene amplification, transgene 290 bp
684 (base pairs), control d9mit sequence 148 bp (Ctrl Allele). Right gel, MR flox construct
685 amplification; flox allele, 345 bp, excised allele 390 bp; white star (*) excision of the flox allele
686 in brachial nerve. See Table1 for primer sequences. For the flox allele, MR fl Rv2 primer (table
687 I) is too distant from MR fl Fw primer for amplification while for the excised allele, MR fl Rv1
688 primer is deleted and MR fl Rv2 is closer to the forward primer and able to amplify the 390 bp
689 fragment. C) Expression of *Mr* in control (Ctrl, N=13) and SCMRKO (N=11) 3-month old male
690 sciatic nerve measured by RT-qPCR using the $\Delta\Delta$ CT method normalizing with *Rpl13a* gene
691 expression; means +/- SEM; Mann Whithney test, ** $p < 0.01$ vs Ctrl; error bars +/- SD.

692

693 **Figure 3. Validation of SCMRKO by immunofluorescence.** Cryosections (12 μ m) of sciatic
694 nerves from 6-month old control MR flox/flox (MRfl/fl, A) and SCMRKO (B) animals were
695 labeled with anti-MR antibody (green) or anti Sox 10 antibody (red) and nucleus were stained
696 with Hoechst (blue), scale: 50 μ m. Control secondary antibodies only (Neg Ctrl) was stained
697 and the same conditions (C). White rectangles in A and B indicate zooming areas.
698 Magnifications of a representative field are shown in D (Control, Ctrl) and E (SCMRKO) with
699 each channel presented separately with a 10 μ m scale; Hoechst (blue), MR labeling (green)

700 Sox10 labeling (red) and a merged channel (lower right panel). White arrows indicate Sox10
701 positive Schwann cell nuclei, co-labeled for MR in Ctrl and with no MR labeling in SCMRKO.
702 The grey arrow indicates a Sox10 positive cell, background-like, weakly positive cell for MR
703 (E).

704

705 **Figure 4. Phenotypic characterization of the motor function of SCMRKO mice.** A) Animals
706 were weight at 2, 5 and 6 months. MRfl/fl control animals are noted C, KO: SCMRKO animals.
707 No significant differences (Mann Whitney test). B) Rotarod test was performed on the same
708 animals, time before fall of the animal (y axis) was measured each month on two to six month
709 old male mice. Experiments stopped after 300 s. C are control mice (N=11), KO for SCMRKO
710 animal (N=12). No difference between groups (Mann Whitney test). Grip strength test (y axis
711 force in grams), with the forelimb only (C) and with four limbs (D), same animals, same
712 notations than in A) and B). No significant difference between groups (Mann Whitney test,
713 comparison of the data for each group every month). Locotronic test, number of errors (E) and
714 travel time (F) are reported in y axis at 6 months (Mann Whitney test), same animals; Ctrl:
715 MRfl/fl mice; no significant differences; error bars +/- SD.

716

717 **Figure 5. Consequences of SCMRKO on sciatic nerve gene and protein expression.**
718 Expression of SC genes *Krox20* (A), *p75* (B), *Pmp22* (C), *Mpz* (D), and *Mbp* (E) were assessed
719 by RT-qPCR from 3-month old mouse sciatic nerve RNA of control (Ctrl, N=14) and SCMRKO
720 (N=11). Expression was measured with the $\Delta\Delta$ CT method normalizing with *Rpl13a* gene
721 expression. Results are expressed as fold change compared to Ctrl sciatic nerve expression
722 which was set to 1. Statistical analysis by Mann Whitney test indicated that differences
723 between the two groups were not significant. F) Upper panel, 4-month old mice Control (Ctrl
724 N=9) or SCMRKO (N=9) were blotted and revealed with anti-MPZ antibody and α Tubulin

725 (α Tub) antibody for normalization. Lower panel, quantification with mean of the control set to
726 1; Mann Whitney test, not significant; error bars +/- SD.

727 **Figure 6. SCMRKO effect on MR signaling pathway in sciatic nerve.** The expression of
728 mineralocorticoid signaling genes *Per1* (A) , *Sgk* (B) and *Gr* (C) was measured by qPCR.
729 Differences between group were not significant with Mann Whitney test except for *Gr*
730 expression, (* $p < 0.05$, vs Ctrl). D). Upper panel, sciatic nerve lysates from 3 to 4 month old
731 male mice. Control (Ctrl N=14) or SCMRKO (N=14) were blotted and revealed with anti-MR
732 antibody and anti- α Tubulin (α Tub) antibody for normalization. Lower panel, signals were
733 quantified and mean of the control was set to 1; * $p < 0.05$ vs Ctrl, Mann Whitney test. E) Upper
734 panel, 4-month old mice Control (Ctrl N=15) or SCMRKO (N=15) were blotted and revealed
735 with anti-GR antibody and α Tubulin (α Tub) antibody for normalization. Lower panel,
736 quantification with mean of the control set to 1; * $p < 0.05$ vs Ctrl Mann Whitney test; error bars
737 +/- SD.

738

739 **Figure 7. Decreased g-ratio in SCMRKO sciatic nerve myelin sheath.** Transmission
740 electron microscopy imaging of control (Ctrl, A) and SCMRKO (B) sciatic nerve cross section.
741 SC, Schwann cell cytoplasm and nuclei; RB, Remak Bundle; Ax, Axon; M, Myelin sheath. C)
742 g-ratios of myelin sheaths from left and right sciatic nerves of 6 month old mice (N=3 animals
743 for each group) were determined with image J and plotted individually from control (Ctrl, circles,
744 mean=0.713) and SCMRKO (squares; mean=0.713); t test; **** $p < 0.0001$ vs Ctrl. D) g-ratios
745 were then plotted according to the distribution of axon perimeter, from $< 10 \mu\text{m}$ to $> 25 \mu\text{m}$ with
746 $5 \mu\text{m}$ perimeter categories; Control (Ctrl), SCMRKO (KO); t test; NS, non-significant; ****
747 $p < 0.0001$ vs Ctrl, ### $p < 0.001$ vs Ctrl. E) With the same data from C, g-ratios were represented
748 in a scatter plot as a function of the axon perimeter for control (Ctrl) and SCMRKO myelin
749 sheaths, with representation of the linear regression; error bars +/- SD.

750

751 **Table 1. Primer sequences.** For each primer pairs, Fw: forward primers, Rv: Reverse primers.
752 D9mit is a control sequence for the genotyping of dhhCre transgene; MR fl, MR flox allele
753 primers from Berger et al (Berger *et al.* 2006). *Hsp60* (*Heat Shock Protein Family D Member*
754 *1*), *Mrlp10* (*Mitochondrial Ribosomal Protein L10*), *Sdha* (*Succinate Dehydrogenase Complex*
755 *Subunit A*) and *Rpl13a* (*Ribosomal Protein L13a*) are normalization genes whose use is
756 indicating accordingly in the corresponding legends. Each of these normalization genes has
757 been selected using the method described in Sundaram et al (Sundaram *et al.* 2019).

758

759






Figure 1

A



B Genotyping



C




Figure 2




Figure 3




Figure 4




Figure 5








Figure 6






Figure 7

Table 1

Primer name	Sequence (5' to 3')
Genotyping	
dhhCre Fw	AACCTTCTCTAGCGGTGCT
dhhCre Rv	AATCCTTGGCTGAAGGGAAT
D9mit Fw	TAACCAACCCTTGAAGGCAC
D9mit Rv	ACGGACAGCATTTTCCA
MR fl Fw	CTGGAGATCTGAACTCCAGGCT
MR fl Rv1	CCTAGAGTTCCTGAGCTGCTGA
MR fl Rv2	TAGAAACACTTCGTAAAGTAGAGCT
qPCR	
<i>Hsp60</i> Fw	AGCACGCTGGTTTTGAACAG
<i>Hsp60</i> Rv	TTCTCCAAACACTGCACCAC
<i>Mrlp10</i> Fw	AGCTGCGGAAACACAAGATC
<i>Mrlp10</i> Rv	AAAAGGGGTAGCAGGTTTCG
<i>Rpl13a</i> Fw	TACGCTGTGAAGGCATCAAC
<i>Rpl13a</i> Rv	TTGGTATTCATCCGCTTCCG
<i>Sdha</i> Fw	AGAAAGGCCAAATGCAGCTC
<i>Sdha</i> Rv	GTGAGAACAAGAAGGCATCAGC
<i>Mr</i> Fw	ATGGAAACCACACGGTGACCT
<i>Mr</i> Rv	AGCCTCATCTCCACACACCAAG
<i>Gr</i> Fw	TTCTGTTCATGGCGTGAGTAC
<i>Gr</i> Rv	CCCTTGGCACCTATTCCAGTT
<i>Fkbp5</i> Fw	AGCTCAGTCCAGCCCATTTC
<i>Fkbp5</i> Rv	TGTAGAACCCACAGCAGCTG
<i>Sgk</i> Fw	TCACTTCTCATTCCAGACCGC
<i>Sgk</i> Rv	ATAGCCCAGGGCACTGGCTA
<i>Per1</i> Fw	CCTGGAAATTGGAGCATAT
<i>Per1</i> Rv	CCTGCTCCGAAATATAGACAATC
<i>Krox20</i> Fw	TGCACCTAGAAACCAGACCTTC
<i>Krox20</i> Rv	TGCCCCGCACTCACAATATTG
<i>Mpz</i> Fw	ATCTCTTTTACCTGGCGCTACC
<i>Mpz</i> Rv	ACTGGATGCGCTCTTTGAAG
<i>Pmp22</i> Fw	TCTGGCAGAACTGTACCACATC
<i>Pmp22</i> Rv	TGGCAGAAGAACAGGAACAGA
<i>MBP</i> Fw	ACTCACACACGAGAACTACCC
<i>MBP</i> Rv	GGTGTTCGAGGTGTCACAATG
<i>P75</i> Fw	AGGTGCCAAGGAGACATGTTC
<i>P75</i> Rv	CGTCAGAGAACGTAACACTGTC